Anzeige
Mehr »
Login
Sonntag, 07.03.2021 Börsentäglich über 12.000 News von 657 internationalen Medien
Bam Bam Resources und die Mega-Kupferlagerstätte in Teslas Hinterhof!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ATYC ISIN: SE0008966295 Ticker-Symbol: 1NP 
Stuttgart
05.03.21
09:39 Uhr
0,153 Euro
-0,002
-1,54 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
INDEX PHARMACEUTICALS HOLDING AB Chart 1 Jahr
5-Tage-Chart
INDEX PHARMACEUTICALS HOLDING AB 5-Tage-Chart

Aktuelle News zur INDEX PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.02.InDex Pharmaceuticals' rights issue is oversubscribed1
INDEX PHARMACEUTICALS Aktie jetzt für 0€ handeln
21.01.Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of InDex Pharmaceuticals Holding AB (24/21)214With effect from January 22, 2021, the subscription rights in InDex Pharmaceuticals Holding AB will be traded on First North Growth Market. Trading will continue up until and including February 03,...
► Artikel lesen
21.01.InDex Pharmaceuticals Holding AB publishes prospectus in connection with a fully guaranteed rights issue3
19.01.XFRA CAPITAL ADJUSTMENT INFORMATION - 19.01.2021155CAPITAL ADJUSTMENT INFORMATION - 20.01.2021:Das Instrument I97 CA13740H1001 CANDENTE GOLD CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 19.01.2021 und ex Kapitalmassnahme am 20.01.2021 The instrument...
► Artikel lesen
14.01.The board of directors of InDex Pharmaceuticals Holding AB has resolved on a fully guaranteed rights issue of approximately MSEK 5331
12.01.Bulletin from the Extraordinary General Meeting in InDex Pharmaceuticals Holding AB (publ)-
09.12.20Notice of Extraordinary General Meeting in InDex Pharmaceuticals Holding AB1
03.12.20InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee for the 2021 Annual General Meeting1
26.11.20InDex Pharmaceuticals to host virtual R&D day on December 8, 20201.348STOCKHOLM, Nov. 26, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) ("InDex") today announced that the company will host a virtual R&D day on Tuesday December 8, 2020 for investors...
► Artikel lesen
24.11.20InDex Pharmaceuticals presents at Redeye Life Science Day 2020-
06.10.20The Lancet Gastroenterology and Hepatology publishes InDex Pharmaceuticals' results of the phase IIb study with cobitolimod204STOCKHOLM, Oct. 6, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study have been published in the high-impact medical journal...
► Artikel lesen
24.08.20InDex Pharmaceuticals to present the successful results of the CONDUCT study at two leading medical conferences263STOCKHOLM, Aug. 24, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the results of the CONDUCT study will be presented orally at two leading gastroenterology...
► Artikel lesen
03.08.20XFRA FRA:New Instruments available on XETRA - 03.08.2020-004397The following instruments on XETRA do have their first trading day 03.08.2020 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag am 03.08.2020 TrdMod InstCode Exch ISIN Name InstGrp InstType...
► Artikel lesen
07.05.20InDex Pharmaceuticals Holding AB (publ) Interim Report January - March 2020280STOCKHOLM, May 7, 2020 /PRNewswire/ -- FDA and EMA endorse the advancement of cobitolimod into phase III studies "The positive responses from the regulators is an important external...
► Artikel lesen
20.04.20Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ)303STOCKHOLM, April 20, 2020 /PRNewswire/ -- The annual general meeting in InDex Pharmaceuticals Holding AB (publ) was held on Monday 20 April 2020 at Setterwalls Advokatbyrå's offices at Sturegatan...
► Artikel lesen
16.04.20InDex Pharmaceuticals Advances Cobitolimod Further Towards Phase III Following Successful Interactions With FDA and EMA256STOCKHOLM, April 16, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the company has received positive responses from FDA and EMA regarding phase III development...
► Artikel lesen
31.03.20InDex Pharmaceuticals Receives Grant From Vinnova for Pre-clinical Development of DIMS Compounds in Inflammation185STOCKHOLM, March 31, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that SEK 2.0 million has been granted from Sweden's innovation agency Vinnova to develop...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1